Supernus Pharmaceuticals GAAP EPS of $0.07 beats by $0.28, revenue of $211.6M beats by $16.44M
Source: SeekingAlpha
2026-02-24 16:26:11 ET
More on Supernus Pharmaceuticals
- Supernus: Outlook For 2026 Positive, Upholding Buy Rating
- Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
- Supernus Pharmaceuticals Q4 2025 Earnings Preview
- Psychedelics stocks could benefit from marijuana rescheduling: Jefferies
- Seeking Alpha’s Quant Rating on Supernus Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Supernus Pharmaceuticals GAAP EPS of $0.07 beats by $0.28, revenue of $211.6M beats by $16.44M
Supernus Pharmaceuticals Inc.
NASDAQ: SUPN
SUPN Trading
-0.18% G/L:
$53.04 Last:
197,960 Volume:
$53.56 Open:
SUPN Latest News
February 26, 2026 09:35:00 am
From Lab to Clinic: Five CNS Companies Advancing Neuroscience Treatments
February 24, 2026 04:05:00 pm
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
SUPN Stock Data
$2,924,306,850
52,293,487
2.13%
131
N/A
Pharmaceuticals
Healthcare
US
Rockville
